title: Genome-wide analysis of loss of heterozygosity in breast infiltrating ductal carcinoma distant normal tissue highlights arm specific enrichment and expansion across tumor stages.
abstract: Studies have shown concurrent loss of heterozygosity (LOH) in breast infiltrating ductal carcinoma (IDC) and adjacent or distant normal tissue. However, the overall extent of LOH in normal tissue and their significance to tumorigenesis remain unknown, as existing studies are largely based on selected microsatellite markers. Here we present the first autosome-wide study of LOH in IDC and distant normal tissue using informative loci deduced from SNP array-based and sequencing-based techniques. We show a consistently high LOH concurrence rate in IDC (mean = 24%) and distant normal tissue (m = 54%), suggesting for most patients (31/33) histologically normal tissue contains genomic instability that can be a potential marker of increased IDC risk. Concurrent LOH is more frequent in fragile site related genes like WWOX (9/31), NTRK2 (10/31), and FHIT (7/31) than traditional genetic markers like BRCA1 (0/23), BRCA2 (2/29) and TP53 (1/13). Analysis at arm level shows distant normal tissue has low level but non-random enrichment of LOH (topped by 8p and 16q) significantly correlated with matched IDC (Pearson r = 0.66, p = 3.5E-6) (topped by 8p, 11q, 13q, 16q, 17p, and 17q). The arm-specific LOH enrichment was independently observed in tumor samples from 548 IDC patients when stratified by tumor size based T stages. Fine LOH structure from sequencing data indicates LOH in low order tissues non-randomly overlap (∼67%) with LOH that usually has longer tract length (the length of genomic region affected by LOH) in high order tissues. The consistent observations from multiple datasets suggest progressive LOH in the development of IDC potentially through arm-specific pile up effect with discernible signature in normal tissue. Our finding also suggests that LOH detected in IDC by comparing to paired adjacent or distant normal tissue are more likely underestimated.
authors.affiliation: Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America.
authors.forename: Xiaoyang
authors.initials: X
authors.lastname: Ruan
authors.affiliation: Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America.
authors.forename: Hongfang
authors.initials: H
authors.lastname: Liu
authors.affiliation: Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America.
authors.forename: Lisa
authors.initials: L
authors.lastname: Boardman
authors.affiliation: Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America.
authors.forename: Jean-Pierre A
authors.initials: JP
authors.lastname: Kocher
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000235:genetics* / Q000473:pathology*; D043283:Chromosome Fragile Sites; D002874:Chromosome Mapping; D002877:Chromosomes, Human; D005260:Female; D055106:Genome-Wide Association Study; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D019656:Loss of Heterozygosity; D009367:Neoplasm Staging
references.citation: Genome Res. 2011 Jun;21(6):961-73
references.pmid: 20980555
references.citation: Genome Res. 2010 Sep;20(9):1297-303
references.pmid: 20644199
references.citation: J Mol Cell Biol. 2011 Feb;3(1):1-3
references.pmid: 21278445
references.citation: Genetics. 1986 Mar;112(3):441-57
references.pmid: 3007275
references.citation: Nucleic Acids Res. 2007;35(10):3478-93
references.pmid: 17478508
references.citation: Genome Res. 2011 Jun;21(6):974-84
references.pmid: 21324876
references.citation: Am J Hum Genet. 2003 Oct;73(4):748-67
references.pmid: 13680524
references.citation: JAMA. 2007 May 16;297(19):2103-11
references.pmid: 17507346
references.citation: Nat Rev Cancer. 2004 Mar;4(3):177-83
references.pmid: 14993899
references.citation: PLoS One. 2012;7(2):e31628
references.pmid: 22347499
references.citation: Nat Genet. 2001 Jun;28(2):169-72
references.pmid: 11381266
references.citation: N Engl J Med. 2007 Dec 20;357(25):2543-51
references.pmid: 18094375
references.citation: Am J Hum Genet. 2006 Jun;78(6):961-72
references.pmid: 16685647
references.citation: Oncogene. 2006 Mar 30;25(14):2060-9
references.pmid: 16331269
references.citation: Nat Genet. 2005 Aug;37(8):899-905
references.pmid: 16007089
references.citation: Ann N Y Acad Sci. 2012 Sep;1267:110-6
references.pmid: 22954224
references.citation: J Pathol. 1999 Dec;189(4):496-503
references.pmid: 10629549
references.citation: Cancer Res. 2000 May 1;60(9):2562-6
references.pmid: 10811140
references.citation: Breast Cancer Res. 2003;5(6):313-9
references.pmid: 14580249
references.citation: Science. 1996 Dec 20;274(5295):2057-9
references.pmid: 8953032
references.citation: Breast Cancer Res. 2005;7(5):R788-95
references.pmid: 16168125
references.citation: Environ Health Perspect. 1996 Aug;104(8):818-9
references.pmid: 8875148
references.citation: Cancer Res. 2007 Jan 1;67(1):93-9
references.pmid: 17210687
references.citation: Cancer Res. 2004 Oct 15;64(20):7231-6
references.pmid: 15492239
references.citation: Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7504-9
references.pmid: 11390984
references.citation: Oncogene. 2011 Sep 8;30(36):3900-6
references.pmid: 21499303
references.citation: Cancer Genet Cytogenet. 2004 Feb;149(1):38-43
references.pmid: 15104281
references.citation: Nat Genet. 2008 Oct;40(10):1253-60
references.pmid: 18776909
references.citation: Curr Opin Genet Dev. 2010 Jun;20(3):282-9
references.pmid: 20381334